Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00519285




Registration number
NCT00519285
Ethics application status
Date submitted
21/08/2007
Date registered
22/08/2007
Date last updated
22/07/2016

Titles & IDs
Public title
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Scientific title
A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer
Secondary ID [1] 0 0
2006-004756-20
Secondary ID [2] 0 0
EFC6546
Universal Trial Number (UTN)
Trial acronym
VENICE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostatic Neoplasms 0 0
Neoplasm Metastasis 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Aflibercept
Treatment: Drugs - Placebo (for aflibercept)
Treatment: Drugs - Docetaxel
Treatment: Drugs - Prednisone or Prednisolone

Placebo comparator: Placebo - Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone

Experimental: Aflibercept - Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone


Treatment: Drugs: Aflibercept
25 mg/ml solution

6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle

Treatment: Drugs: Placebo (for aflibercept)
Sterile aqueous buffered solution identical to aflibercept

1-hour IV on Day 1 of each 3-Week cycle

Treatment: Drugs: Docetaxel
Marketed formulation

75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)

Treatment: Drugs: Prednisone or Prednisolone
Marketed formulation

5 mg twice daily PO from day 1 continuously
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival Time
Timepoint [1] 0 0
From randomization up to the cut-off date (median follow-up of 35.4 months)
Secondary outcome [1] 0 0
Prostate Specific Antigen Response Rate
Timepoint [1] 0 0
Before randomization (baseline) then every 3 weeks up to PSA progression (=25% increase) or the cut-off date, whichever occurred first
Secondary outcome [2] 0 0
Time to Skeletal Related Events
Timepoint [2] 0 0
From randomization up to the cut-off date (median follow-up of 35.4 months)
Secondary outcome [3] 0 0
Progression Free Survival Time
Timepoint [3] 0 0
From randomization up to the cut-off date (median follow-up of 35.4 months)
Secondary outcome [4] 0 0
Tumor Response Rate in Participants With Measurable Disease
Timepoint [4] 0 0
Before randomization (baseline) then every 3 months up to tumor progression (=25% increase) or the cut-off date, whichever occurred first
Secondary outcome [5] 0 0
Prostate Specific Antigen Progression-free Survival Time
Timepoint [5] 0 0
From randomization up to the cut-off date (median follow-up of 35.4 months)
Secondary outcome [6] 0 0
Pain Progression-free Survival Time
Timepoint [6] 0 0
From randomization up to the cut-off date (median follow-up of 35.4 months)
Secondary outcome [7] 0 0
Pain Response Rate
Timepoint [7] 0 0
Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first
Secondary outcome [8] 0 0
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life
Timepoint [8] 0 0
Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first
Secondary outcome [9] 0 0
Number of Participants With Adverse Events as a Measure of Safety
Timepoint [9] 0 0
From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days
Secondary outcome [10] 0 0
Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept
Timepoint [10] 0 0
Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug

Eligibility
Key inclusion criteria
* Histologically- or cytologically-confirmed prostate adenocarcinoma;
* Metastatic disease;
* Progressive disease while receiving hormonal therapy or after surgical castration;
* Effective castration.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago;
* Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF receptor inhibitors;
* Eastern Cooperative Oncology Group (ECOG) performance status >2.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2012
Sample size
Target
Accrual to date
Final
1224
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Administrative Office - Macquarie Park
Recruitment postcode(s) [1] 0 0
- Macquarie Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New Jersey
Country [2] 0 0
Argentina
State/province [2] 0 0
Buenos Aires
Country [3] 0 0
Belgium
State/province [3] 0 0
Diegem
Country [4] 0 0
Brazil
State/province [4] 0 0
Sao Paulo
Country [5] 0 0
Canada
State/province [5] 0 0
Laval
Country [6] 0 0
Chile
State/province [6] 0 0
Providencia Santiago
Country [7] 0 0
Croatia
State/province [7] 0 0
City of Zagreb
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Praha
Country [9] 0 0
Denmark
State/province [9] 0 0
Horsholm
Country [10] 0 0
Estonia
State/province [10] 0 0
Tallinn
Country [11] 0 0
France
State/province [11] 0 0
Paris
Country [12] 0 0
Germany
State/province [12] 0 0
Frankfurt
Country [13] 0 0
Hong Kong
State/province [13] 0 0
Hong Kong
Country [14] 0 0
Hungary
State/province [14] 0 0
Budapest
Country [15] 0 0
Israel
State/province [15] 0 0
Natanya
Country [16] 0 0
Italy
State/province [16] 0 0
Milan
Country [17] 0 0
Korea, Republic of
State/province [17] 0 0
Seoul
Country [18] 0 0
Netherlands
State/province [18] 0 0
Gouda
Country [19] 0 0
Poland
State/province [19] 0 0
Warsaw
Country [20] 0 0
Portugal
State/province [20] 0 0
Porto Salvo
Country [21] 0 0
Russian Federation
State/province [21] 0 0
Moscow
Country [22] 0 0
Singapore
State/province [22] 0 0
Singapore
Country [23] 0 0
South Africa
State/province [23] 0 0
Gauteng
Country [24] 0 0
Spain
State/province [24] 0 0
Barcelona
Country [25] 0 0
Sweden
State/province [25] 0 0
Bromma
Country [26] 0 0
Switzerland
State/province [26] 0 0
Geneva
Country [27] 0 0
Taiwan
State/province [27] 0 0
Taipei
Country [28] 0 0
Turkey
State/province [28] 0 0
Istanbul
Country [29] 0 0
Ukraine
State/province [29] 0 0
Kiev
Country [30] 0 0
United Kingdom
State/province [30] 0 0
Guildford Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Regeneron Pharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).

The secondary objectives were:

* To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL);
* To assess the overall safety in both treatment arms;
* To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;
* to determine immunogenicity of IV aflibercept.
Trial website
https://clinicaltrials.gov/study/NCT00519285
Trial related presentations / publications
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.
van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015 Apr;26(4):743-749. doi: 10.1093/annonc/mdu569. Epub 2014 Dec 15.
de Liano AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00519285